Statistically significant differences in CXCL-8 concentrations between tumor stages were first established using the Kruskal–Wallis test (p = 0.029; Figure 2) and then confirmed by the post hoc Dwass–Steele–Critchlow–Fligner test in patients with stage III and IV of CRC (p = 0.021; data not shown). Here, CXCL8 is linked to neoplasm.